Patents Assigned to Chiba University
  • Patent number: 10006005
    Abstract: Provided are a method of inducing differentiation of pluripotent stem cells, such as induced pluripotent stem cells (hereinafter abbreviated as iPS cells), to hepatocytes in a short period of time, and a substance to be used in the method. Specifically, provided are a method of producing a cell culture formed substantially of hepatoblasts, the method including culturing pluripotent stem cells, such as iPS cells, in a culture medium having a composition shown in Table 1 below, and a culture medium for inducing differentiation of pluripotent stem cells into hepatoblasts, which has a composition shown in Table 1 below.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: June 26, 2018
    Assignee: National University Corporation Chiba University
    Inventor: Minoru Tomizawa
  • Patent number: 9963731
    Abstract: The present invention provides a method of producing a carotenoid having 50 carbon atoms which comprises culturing, in a medium, a cell transformed with a mutant phytoene desaturase gene and obtaining the carotenoid having 50 carbon atoms from the culture. The mutant phytoene desaturase gene has an introduced mutation to encode a mutant phytoene desaturase having an enhanced activity to desaturate a carotenoid backbone compound of 50 carbon atoms.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: May 8, 2018
    Assignee: National University Corporation Chiba University
    Inventors: Daisuke Umeno, Maiko Furubayashi, Norihiko Misawa, Shinichi Takaichi
  • Patent number: 9957262
    Abstract: Provided are a compound represented by formula (I) or (II), a salt thereof, or solvates of the compound and salt, having an analgesic effect and high metabolic stability. Further provided are the following: an analgesic obtained from the compound, a salt thereof, or solvates of the compound and salt; a pharmaceutical composition containing the compound, a salt thereof, or solvates of the compound and salt; an analgesic treatment method using the compound, a salt thereof, or solvates of the compound and salt; and a use of the compound, a salt thereof, or solvates of the compound and salt, in the production of an analgesic composition.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: May 1, 2018
    Assignee: National University Corporation Chiba University
    Inventor: Hiromitsu Takayama
  • Patent number: 9937163
    Abstract: A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: April 10, 2018
    Assignee: National University Corporation Chiba University
    Inventors: Kenji Hashimoto, Masaomi Iyo, Kaori Koike
  • Patent number: 9872833
    Abstract: An object of the present invention is to provide a drug delivery system capable of sustainedly releasing a drug noninvasively at any given point in time. The present invention relates to a liposome complex comprising a liposome membrane-constituting substance bonded to a light-absorbing compound having an absorption wavelength in the near-infrared region, selected from the group consisting of indocyanine green dyes, phthalocyanine dyes, squarylium dyes, croconium dyes, and diimmonium dyes.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: January 23, 2018
    Assignees: National University Corporation Tottori University, National University Corporation Chiba University
    Inventors: Yoshiharu Okamoto, Yutaka Tamura, Akiko Suganami, Hideki Hayashi, Tomoyuki Madono, Hisahiro Matsubara, Taro Toyota
  • Patent number: 9872841
    Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: January 23, 2018
    Assignee: National University Corporation Chiba University
    Inventor: Kenji Hashimoto
  • Publication number: 20170343547
    Abstract: The present inventors have surprisingly found that a deoxyhypusine synthase (DHPS) gene, which was previously reported to correlate with prostate cancer and cervical cancer, is highly responsive to arteriosclerosis or digestive system cancer, whereby the gene can be used as a desired marker for arteriosclerosis or digestive system cancer. The present invention has been accomplished on the basis of this finding. Specifically, the present invention provides a method for determining arteriosclerosis or digestive system cancer, which method includes detecting expression of a deoxyhypusine synthase gene in a test sample (preferably a blood sample), and determining arteriosclerosis or digestive system cancer of a test subject from which the test sample has been obtained, on the basis of an increase in the gene expression as an index.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 30, 2017
    Applicants: FUJIKURA KASEI CO., LTD., National University Corporation Chiba University
    Inventors: Rika NAKAMURA, Hideyuki KURODA, Go TOMIYOSHI, Takaki HIWASA, Masaki TAKIGUCHI, Naokatsu SAEKI
  • Publication number: 20170334982
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 23, 2017
    Applicant: National University Corporation Chiba University
    Inventors: Toshinori Nakayama, Hiroyuki Hosokawa, Koji Tokoyoda, Koji Hayashizaki, Akane Suzuki
  • Publication number: 20170299580
    Abstract: Provided are novel polymer particles for carrying a physiologically active substance and a method of preparing the same. The polymer particles for carrying a physiologically active substance can provide an analytical reagent, which has high analytical precision and sensitivity and can be stably prepared; can easily and precisely control the amount of functional groups carrying the physiologically active substance; can introduce, onto the surface of latex particles, a hydrophilic compound for inhibiting a nonspecific reaction; and can be prepared to have a narrow and uniform particle size distribution.
    Type: Application
    Filed: September 2, 2015
    Publication date: October 19, 2017
    Applicants: LSI Medience Corporation, National University Corporation Chiba University
    Inventors: Atsushi KADOWAKI, Tatsuo TANIGUCHI, Yusuke SASAKI, Naho KONISHI
  • Patent number: 9758574
    Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: September 12, 2017
    Assignee: National University Corporation Chiba University
    Inventors: Toshinori Nakayama, Hiroyuki Hosokawa, Koji Tokoyoda, Koji Hayashizaki, Akane Suzuki
  • Patent number: 9739675
    Abstract: A surface acoustic wave (SAW) sensor includes a surface acoustic wave material and a comb-teeth electrode. The surface acoustic wave material is to be arranged at a place where the surface acoustic wave material is distorted by physical quantity such as stress. The comb-teeth electrode is arranged on the surface of the surface acoustic wave material to excite a surface acoustic wave to the surface acoustic wave material. The surface acoustic wave material has a sapphire board and a ScAlN film arranged on a surface of the sapphire board.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: August 22, 2017
    Assignees: DENSO CORPORATION, TOHOKU UNIVERSITY, National University Corporation Chiba University
    Inventors: Akihiko Teshigahara, Toshihiko Takahata, Takao Iwaki, Shuji Tanaka, Masayoshi Esashi, Kenya Hashimoto
  • Publication number: 20170218394
    Abstract: Methods of producing hepatocyte lineage cells are provided. The method can include transfecting a cell with one or more expression vectors. For example, a cell can be transfected with a first expression vector containing a first gene that encodes CCAAT/enhancer binding protein alpha (CEBPA), a second expression vector containing a second gene that encodes CCAAT/enhancer binding protein beta (CEBPB), a third expression vector containing a third gene that encodes forkhead box A1 (FOXA1), and a fourth expression vector containing a fourth gene that encodes forkhead box A3 (FOXA3). The method can include culturing the transfected cell obtained in a growth environment. The transfected cell can be cultured in Williams' E medium, ReproFF (feeder-free media maintaining pluripotency) medium, or both. Transfected and/or hepatocyte lineage cells obtained by a method of the present invention are also provided.
    Type: Application
    Filed: January 27, 2017
    Publication date: August 3, 2017
    Applicant: National University Corporation Chiba University
    Inventor: Minoru Tomizawa
  • Publication number: 20170191103
    Abstract: The present invention provides a method of producing a carotenoid having 50 carbon atoms which comprises culturing, in a medium, a cell transformed with a mutant phytoene desaturase gene and obtaining the carotenoid having 50 carbon atoms from the culture. The mutant phytoene desaturase gene has an introduced mutation to encode a mutant phytoene desaturase having an enhanced activity to desaturate a carotenoid backbone compound of 50 carbon atoms.
    Type: Application
    Filed: December 20, 2016
    Publication date: July 6, 2017
    Applicant: National University Corporation Chiba University
    Inventors: Daisuke Umeno, Maiko Furubayashi, Norihiko Misawa, Shinichi Takaichi
  • Publication number: 20170067124
    Abstract: A method for quantitatively evaluating chromatin structural changes using pixel imaging of the nucleus is provided. Pixel imaging of the nucleus can include capturing one or more images of a nucleus of one or more nucleic acid stain treated cells. The stain intensity can be measured by quantitating the intensity. The mean and/or standard deviation of stain intensity per pixel can be used to determine chromatin condensation levels or chromatin structural change.
    Type: Application
    Filed: November 16, 2016
    Publication date: March 9, 2017
    Applicant: National University Corporation Chiba University
    Inventor: Naoto Yamaguchi
  • Patent number: 9562220
    Abstract: The present invention provides a method of producing a carotenoid having 50 carbon atoms which comprises culturing, in a medium, a cell transformed with a mutant phytoene desaturase gene and obtaining the carotenoid having 50 carbon atoms from the culture. The mutant phytoene desaturase gene has an introduced mutation to encode a mutant phytoene desaturase having an enhanced activity to desaturate a carotenoid backbone compound of 50 carbon atoms.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: February 7, 2017
    Assignee: National University Corporation Chiba University
    Inventors: Daisuke Umeno, Maiko Furubayashi, Norihiko Misawa, Shinichi Takaichi
  • Patent number: 9528141
    Abstract: A method for quantitatively evaluating chromatin structural changes using pixel imaging of the nucleus is provided. Pixel imaging of the nucleus can include capturing one or more images of a nucleus of one or more nucleic acid stain treated cells. The stain intensity can be measured by quantitating the intensity. The mean and/or standard deviation of stain intensity per pixel can be used to determine chromatin condensation levels or chromatin structural change.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: December 27, 2016
    Assignee: National University Corporation Chiba University
    Inventor: Naoto Yamaguchi
  • Patent number: 9530920
    Abstract: A photoelectric conversion device which is a semiconductor device comprising a first conductive layer having a first conductivity type; a second conductive layer formed on the first conductive layer and having a second conductivity type; and a photosensitizing layer formed between the first conductive layer and the second conductive layer, wherein charge carriers generated by photoelectric conversion in the photosensitizing layer are freely movable to at least one of the first conductive layer and the second conductive layer.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: December 27, 2016
    Assignee: National University Corporation Chiba University
    Inventors: Akihiko Yoshikawa, Yoshihiro Ishitani, Kazuhide Kusakabe
  • Publication number: 20160341740
    Abstract: Methods of diagnosing, confirming a diagnosis of, and determining a predisposition for a bipolar disorder in a subject are provided. An amount of at least one of biomarker from the cerebrospinal fluid and/or serum of a subject is measured, for example, isocitric acid. The amount of the at least one biomarker can be compared with a control amount of the at least one biomarker in a corresponding sample collected from a subject without the bipolar disorder. An increase or decrease in the amount of the particular biomarker or biomarkers measured can be indicative that the subject has the bipolar disorder or a predisposition for the bipolar disorder. Methods of identifying a compound for preventing and/or treating a bipolar disorder are also provided based on the expression level of an isocitric acid dehydrogenase 3 alpha and/or beta-subunit gene, and/or based on one or more metabolite biomarker.
    Type: Application
    Filed: May 17, 2016
    Publication date: November 24, 2016
    Applicant: National University Corporation Chiba University
    Inventors: Kenji Hashimoto, Takashi Futamura, Noriko Yoshimi, Takeo Yoshikawa, Yoshimi Iwayama, Mikael Landen
  • Patent number: 9494594
    Abstract: Provided is a method of determining a therapeutic effect of cancer chemotherapy with an anticancer drug obtained by blending three ingredients, i.e., tegafur, gimeracil, and oteracil potassium as active ingredients (hereinafter abbreviated as S-1) quickly, simply, and accurately before carrying out the cancer chemotherapy. Specifically, provided is a method of determining an administration effect in chemotherapy with S-1, the method comprising: a step (a) of measuring expression level of a decorin gene in a biological sample collected from a subject to be diagnosed; and a step (b) of determining an administration effect of S-1 based on the expression level of the gene obtained from the measurement.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: November 15, 2016
    Assignee: National University Corporation Chiba University
    Inventors: Hideki Tanzawa, Atsushi Kasamatsu, Katsuhiro Uzawa
  • Patent number: 9460637
    Abstract: Provided is a stethoscopy training system which is inexpensive and has a simple configuration, without using a device which measures a respiratory operation of a simulated patient. The stethoscopy training system for this objective is formed from: a simulated stethoscope (1) having a sound acquisition unit further comprising a location display means (1d), a tube, and ear pipes; a location sensing means (2) for sensing the location of the sound acquisition unit; biological sound database (3); a biological sound reproducing means (4); and a timing display means (5) for displaying a timing of a repetition of a reproduced respiratory sound. The database retains as information biological sounds which are prerecorded from actual patients in correspondence with chest locations.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: October 4, 2016
    Assignees: National University Corporation Chiba University, Kenzmedico Co., Ltd.
    Inventors: Toshiya Nakaguchi, Masahiro Tanabe